How Has Treatment for Advanced DLBCL Evolved?

By The Fellow on Call - Last Updated: October 15, 2023

In this episode of “The Fellow on Call,” hosts Ronak Mistry, DO; Vivek Patel, MD; and Dan Hausrath, MD; continue their series focusing on diffuse large B-cell lymphoma (DLBCL).

In the third episode of the series, the hosts discuss how to manage DLBCL in the advanced stages of the disease and highlight how to identify high-risk features on a pathology report. They review historical approaches to treatment and discuss studies that compare CHOP and R-CHOP in advanced DLBCL.

The hosts also discuss the role of central nervous system prophylaxis in DLBCL, questions surrounding autologous hemopoietic stem cell transplantation in certain patients, and considerations surrounding imaging during treatment.

This podcast originally appeared on thefellowoncall.com.

How to Approach Relapsed DLBCL After CAR-T Therapy

What to Know About Relapsed Disease Treatment After 12 Months in DLBCL

How to Approach Patients with Primary Refractory DLBCL

How Is Cellular Therapy Changing Care for Hematologic Malignancies?

What Does the Latest Research Say About Managing DLBCL?

Editorial Board

Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine

Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center

Elias Jabbour, MDExecutive Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center

Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University

Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center

Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch

Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer

How Has Treatment for Advanced DLBCL Evolved?

Related